Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Evolutionary dynamics of cancer in response to targeted combination therapy.

Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, Lipson EJ, Chapman PB, Diaz LA Jr, Vogelstein B, Nowak MA.

Elife. 2013 Jun 25;2:e00747. doi: 10.7554/eLife.00747.

2.

BRAF inhibitors in cancer therapy.

Hertzman Johansson C, Egyhazi Brage S.

Pharmacol Ther. 2014 May;142(2):176-82. doi: 10.1016/j.pharmthera.2013.11.011. Epub 2013 Dec 8. Review.

PMID:
24325952
3.

Stochastic modeling of drug resistance in cancer.

Komarova N.

J Theor Biol. 2006 Apr 7;239(3):351-66. Epub 2005 Sep 27.

PMID:
16194548
4.

Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer.

Sameen S, Barbuti R, Milazzo P, Cerone A, Del Re M, Danesi R.

J Theor Biol. 2016 Jan 21;389:263-73. doi: 10.1016/j.jtbi.2015.10.019. Epub 2015 Nov 6.

5.
6.

[Current Progress and Feasibility of Using Molecular-Targeted Agent Combinations for Metastatic Colorectal Cancer].

Masuishi T, Muro K.

Gan To Kagaku Ryoho. 2016 Apr;43(4):408-12. Japanese.

PMID:
27220786
7.

Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.

Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC, Proia DA.

Mol Cancer Ther. 2014 Feb;13(2):353-63. doi: 10.1158/1535-7163.MCT-13-0481. Epub 2014 Jan 7.

8.
9.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

10.

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.

Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.

Lancet Oncol. 2015 Oct;16(13):1389-98. doi: 10.1016/S1470-2045(15)00087-X.

PMID:
26433819
11.

Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.

Foo J, Michor F.

PLoS Comput Biol. 2009 Nov;5(11):e1000557. doi: 10.1371/journal.pcbi.1000557. Epub 2009 Nov 6. Erratum in: PLoS Comput Biol. 2009 Dec;5(12). doi: 10.1371/annotation/d5844bf3-a6ed-4221-a7ba-02503405cd5e.

12.

Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.

Capalbo C, Marchetti P, Coppa A, Calogero A, Anastasi E, Buffone A, Belardinilli F, Gulino M, Frati P, Catalano C, Cortesi E, Giannini G, Gulino A.

Cancer Biol Ther. 2014 Jul;15(7):826-31. doi: 10.4161/cbt.28878. Epub 2014 Apr 22.

13.

Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.

Zia Y, Chen L, Daud A.

Expert Opin Pharmacother. 2015;16(14):2257-63. doi: 10.1517/14656566.2015.1085509. Epub 2015 Sep 2. Review.

PMID:
26331795
14.

Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.

Mignani S, Bryszewska M, Klajnert-Maculewicz B, Zablocka M, Majoral JP.

Biomacromolecules. 2015 Jan 12;16(1):1-27. doi: 10.1021/bm501285t. Epub 2014 Dec 11. Review.

PMID:
25426779
15.

Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.

Al-Marrawi MY, Saroya BS, Brennan MC, Yang Z, Dykes TM, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):703-10. doi: 10.4161/cbt.25191. Epub 2013 Jun 13.

16.

Vemurafenib.

Garbe C, Abusaif S, Eigentler TK.

Recent Results Cancer Res. 2014;201:215-25. doi: 10.1007/978-3-642-54490-3_13. Review.

PMID:
24756795
17.

BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.

Sloot S, Zager JS, Kudchadkar RR, Messina JL, Benedict JJ, Gonzalez RJ, DeConti R, Turner LM, McCardle T, Smalley KS, Weber JS, Sondak VK, Gibney GT.

Melanoma Res. 2016 Feb;26(1):83-7. doi: 10.1097/CMR.0000000000000214.

PMID:
26731560
18.

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.

Kim A, Cohen MS.

Expert Opin Drug Discov. 2016 Sep;11(9):907-16. doi: 10.1080/17460441.2016.1201057. Epub 2016 Jun 23. Review.

19.

Second-line systemic therapy for metastatic colorectal cancer.

Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X.

Cochrane Database Syst Rev. 2017 Jan 27;1:CD006875. doi: 10.1002/14651858.CD006875.pub3. Review.

PMID:
28128439
20.

Cancer therapy: an evolved approach.

Willyard C.

Nature. 2016 Apr 14;532(7598):166-8. doi: 10.1038/532166a. No abstract available.

PMID:
27075079

Supplemental Content

Support Center